David Harrington

This email address is being protected from spambots. You need JavaScript enabled to view it.



Our research focuses on two main areas: the computational and mathematical issues that arise in the design and analysis of clinical trials, and clinical trials examining the treatment of lymphoma, leukemia, and lung cancer.


Methodologic research in statistical issues concentrates on mathematical models for efficient design s of multicenter clinical trials of cancer treatment, the analysis of time-to-event data, and the de sign of population-based studies of cancer care. This research examines early-stopping for clinical trials, the analysis of high-dimensional data with event-time endpoints, and analytic methods for population-based methods of cancer care.


Collaborative research in cancer is conducted with investigators at the Dana-Farber/Harvard Cancer Center and the Cancer Care Outcomes Research and Surveillance Consortium (CanCORS). CanCORS is a national survey, funded by the National Cancer Institute, to study patterns of care in lung and colorectal cancer, with an emphasis on disparities in care by race, ethnicity, and age. Our department serves as the Statistical Coordinating Center for CanCORS.



Dr. Harrington received his PhD in mathematics from the University of Maryland in 1976, has been a fac ulty member at DFCI and the Harvard School of Public Health since 1984, and has served as chair of the DFCI Department of Biostatistical Science since 1998. His research focuses on statistical issues that arise in clinical trials, with special focus on lymphoma and lung cancer, and on the delivery of cancer care.


Recent Publications

Harrington D, Parmigiani G. Adaptive Randomization of Neratinib in Early
Breast Cancer. N Engl J Med. 2016 Oct 20;375(16):1593-4.


Harrington D, Parmigiani G. I-SPY 2--A Glimpse of the Future of Phase 2 Drug
Development? N Engl J Med. 2016 Jul 7;375(1):7-9.


Rader KA, Lipsitz SR, Fitzmaurice GM, Harrington DP, Parzen M, Sinha D.
Bias-corrected estimates for logistic regression models for complex surveys with
application to the United States' Nationwide Inpatient Sample. Stat Methods Med
Res. 2015 Aug 11.


Karia PS, Jambusaria-Pahlajani A, Harrington DP, Murphy GF, Qureshi AA,
Schmults CD. Evaluation of American Joint Committee on Cancer, International
Union Against Cancer, and Brigham and Women's Hospital tumor staging for
cutaneous squamous cell carcinoma. J Clin Oncol. 2014 Feb 1;32(4):327-34.


Loong B, Zaslavsky AM, He Y, Harrington DP. Disclosure control using partiallysynthetic data for large-scale health surveys, with applications to CanCORS. Stat Med. 2013 May 13.


Schwede M, Spentzos D, Bentink S, Hofmann O, Haibe-Kains B, Harrington D, Quackenbush J, Culhane AC. Stem cell-like gene expression in ovarian cancer predicts type II subtype and prognosis. PLoS One. 2013;8(3):e57799.


Blinder VS, Norris VW, Peacock NW, Griggs JJ, Harrington DP, Moore A,
Theriault RL, Partridge AH; American Society of Clinical Oncology Breast Cancer Registry Pilot Steering Group. Patient perspectives on breast cancer treatment plan and summary documents in community oncology care: a pilot program. Cancer. 2013 Jan 1;119(1):164-72.


Catalano PJ, Ayanian JZ, Weeks JC, Kahn KL, Landrum MB, Zaslavsky AM, Lee J, Pendergast J, Harrington DP; Cancer Care Outcomes Research Surveillance Consortium. Representativeness of participants in the cancer care outcomes research and surveillance consortium relative to the surveillance, epidemiology, and end results program. Med Care. 2013 Feb;51(2):e9-15.



Related Links

Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium - The Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium is an NCI-funded study that is a network of sites around the country that are conducting a population-based study of access to and outcomes from cancer care, with special focus on ethnic subgroups and subgroups defined by age.